Biotech Values

[caravon]

FDA will be under strong pressure to approve the ABBV/ENTA 3-DAA HCV regimen in the next 4-5 months.

As for today $20M milestone to ENTA, it has increased Enta Market Cap by 3%. The EU submission will also increase Enta Market Cap by 3%. And finally, the approval in US and EU will increase Enta Market Cap by another 23%.

Things are becoming very interesting taking into account that there are lots of money to be made in the HCV treatment areal